Skip to main content

Table 1 Population characteristics and clonidine concentration at steady state

From: Clonidine in the treatment of adolescent chronic fatigue syndrome: a pilot study for the NorCAPITAL trial

Number (male/female)

5 (3/2)

 

Median (range)

Age (years)

14

 

(14–19)

BMI (kg/m2)

20.8

 

(17.0-22.4)

Disease duration (months)

34

 

(27–48)

C0 of clonidine (μg/L),

0.21

 

(0.18-0.36)

Cmax of clonidine (μg/L)

0.41

 

(0.38-0.56)